Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Current Assets (2018 - 2025)

BioNexus Gene Lab's Current Assets history spans 8 years, with the latest figure at $5.4 million for Q4 2025.

  • Quarterly results put Current Assets at $5.4 million for Q4 2025, down 26.67% from a year ago — trailing twelve months through Dec 2025 was $5.4 million (down 26.67% YoY), and the annual figure for FY2025 was $5.4 million, down 26.67%.
  • Current Assets for Q4 2025 was $5.4 million at BioNexus Gene Lab, down from $5.6 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $8.3 million in Q3 2023 to a low of $5.2 million in Q2 2023.
  • The 5-year median for Current Assets is $6.8 million (2022), against an average of $6.7 million.
  • The sharpest move saw Current Assets soared 927.78% in 2021, then decreased 26.93% in 2022.
  • Year by year, Current Assets stood at $7.1 million in 2021, then fell by 15.78% to $6.0 million in 2022, then soared by 33.63% to $8.0 million in 2023, then decreased by 7.66% to $7.4 million in 2024, then dropped by 26.67% to $5.4 million in 2025.
  • According to Business Quant data, Current Assets over the past three periods came in at $5.4 million, $5.6 million, and $6.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.